Group 1 - The company held its 20th temporary board meeting on July 28, 2025, where it approved the acquisition of 25% equity in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. from Shanghai Yanlin Biotechnology Co., Ltd. [1][12] - The acquisition was approved with 7 votes in favor, 0 against, and 0 abstentions, and the related directors recused themselves from the vote [2][5][12] - The transaction is classified as a related party transaction due to the controlling relationship between the parties involved [8][14] Group 2 - The total assessed value of 100% equity in Shanghai Zhongyuan Jisheng is RMB 15.2783 million, with the agreed transfer price for the 25% stake set at RMB 3,819,575 [9][10][20] - The transaction does not constitute a major asset restructuring and does not require shareholder approval [9][13] - The company aims to enhance operational efficiency and increase resource investment in adult health cell storage business through this acquisition [30][31] Group 3 - The company plans to establish its East China headquarters in Shanghai and has signed a real estate lease agreement with Shanghai Yanlin Biotechnology Co., Ltd. [34][36] - The total rent for the leased property is RMB 12,239,910, with a rental period from August 1, 2025, to July 31, 2028 [35][36] - The rental price is set at RMB 6 per day per square meter, with options for payment that include discounts for upfront payments [36][49] Group 4 - The lease agreement includes provisions for shared use of certain areas and specifies that the company will not incur additional business dependencies on related parties [56][57] - The company’s independent directors have reviewed and approved the lease agreement, confirming that it aligns with the company's strategic planning and does not harm shareholder interests [57][58]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●交易简要内容：基于公司战略规划需要，公司计划在上海设立华东总部。 经友好协商，公司拟与上海延藜生物技术有限公司（以下简称"上海延藜公司"） 签订房地产租赁合同，公司向上海延藜公司租赁其房地产作为华东总部办公使 用，具体房地产为上海延藜公司从上海春光实业有限公司承租的上海市普陀区泸 定路 276 弄 5 号楼（共 5 层）。其中 1 层部分区域提供公司无偿使用，作为公司 产品体验中心；2 层公司与上海延藜公司无偿共用，用作客户接待区域。第 3、4、 ●至本次关联交易为止，过去 12 个月与同一关联人以及与不同关联人进行 的交易类别相关的关联交易（日常关联交易除外）的累计次数为 2 次：协和干细 胞基因工程有限公司继续委托天津市红磡物业经营管理有限公司负责天津市华 苑 产 业 园 区 梅苑 路 12 号 区 域内 的物 业管 理服务 ，合 同 期 服务 费用 总 计 为 中源济生细胞科技有限公司 25%股权，转让价格为人民币 3,819,575 元。 一、关联交易概 ...

Core Viewpoint - The company aims to enhance operational decision-making efficiency by acquiring a 25% stake in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. from Shanghai Yanlin Biotechnology Co., Ltd. for RMB 3.8196 million, making it a wholly-owned subsidiary [1] Group 1 - The acquisition is intended to increase resource investment in the adult health cell storage business [1] - The transaction price for the stake is RMB 3.8196 million [1] - Post-transaction, the company will leverage existing facilities and market channels to improve operational synergy and develop a complete business loop for the adult health cell storage business in the East China region [1]